Newron Pharmaceuticals

Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease (PD) is sold in Europe, Japan, the United States and other regions. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase III trial programme targeting schizophrenia.

Equities

Equities by Sector

Sectors

Thematics

Latest

Inside the mind of investors: International Biotechnology Trust

Borussia Dortmund – executive interviews

UK equities: A generational opportunity?

Audiovisual

Latest

Uncovering Trusts – Finsbury Growth & Income Trust (FGT)

Take on Trusts – December 2024

Vantage: Gresham House Energy Storage Fund – Navigating challenges in energy storage

About Edison

About Edison

Careers

Newron Pharmaceuticals (SIX: NWRN)

Latest Insights

Newron Pharmaceuticals — Evenamide licence agreement in Japan

Newron Pharmaceuticals — Moving full steam towards pivotal studies

Newron Pharmaceuticals — Evenamide road to registration and beyond

Newron Pharmaceuticals — Evenamide potential for treatment of schizophrenia

Sector

Equity Analyst

Key Management

Research

Newron Pharmaceuticals — Crucial upcoming datasets for evenamide

Newron Pharmaceuticals — Encouraging efficacy data from evenamide trial

Newron Pharmaceuticals — Positive readout highlights evenamide potential

Newron Pharmaceuticals — Positive top-line data to support clinical progress

Newron Pharmaceuticals — A year ahead of clinical milestones for evenamide

Newron Pharmaceuticals — Positive interim trial results in schizophrenia

Newron Pharmaceuticals — Evenamide catalyst approaching

Newron Pharmaceuticals — Evenamide efficacy still going strong after 52 weeks

Newron Pharmaceuticals — Evenamide potential expanding in schizophrenia

Newron Pharmaceuticals — Pivotal progress on schizophrenia therapy

Newron Pharmaceuticals — Evenamide validation underway

Newron Pharmaceuticals — Evenamide Phase III at 30mg twice daily dose

Newron Pharmaceuticals — Long-term generic challenge to Xadago

Newron Pharmaceuticals — Gate not yet open to Phase III

Newron Pharmaceuticals — Dyskinesia deal delivered

Newron Pharmaceuticals — Evenamide Phase II completes recruitment

Newron Pharmaceuticals — Schizophrenia development adds value

Newron Pharmaceuticals – EKF interview

Newron Pharmaceuticals — Evenamide trial progressing well

Newron Pharmaceuticals — Evenamide safety trial underway

Newron Pharmaceuticals — Evenamide focus, Supernus to sell Xadago in US

Newron Pharmaceuticals — Sarizotan fails to shine

Newron Pharmaceuticals — Seeing STARS

Newron Pharmaceuticals — Xadago slows, Evenamide lags but STARS ahead

Newron Pharmaceuticals — Evenamide down but not out

Newron Pharmaceuticals — Moving towards R&D inflection points

Newron Pharmaceuticals — Next up – R&D day

Newron Pharmaceuticals — 2018 focus on the CNS pipeline

Newron Pharmaceuticals — Xadago receives FDA approval in PD

Newron Pharmaceuticals — Marching into 2017

Newron Pharmaceuticals — Update 2 September 2016

Newron Pharmaceuticals — Update 31 March 2016

Newron Pharmaceuticals — Update 17 March 2016

Newron Pharmaceuticals — Update 14 March 2016

Newron Pharmaceuticals — Update 20 December 2015

Further insights

Newron Pharmaceuticals: EKF 2023 QuickView

Deutsches Eigenkapitalforum (EKF) 2022 healthcare

Deutsches Eigenkapitalforum (EKF) 2022